Trial Profile
A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Fludrocortisone; Hydrocortisone
- Indications Congenital adrenal hyperplasia
- Focus Therapeutic Use
- Acronyms ARCH
- 30 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Nov 2020 Planned End Date changed from 1 Aug 2024 to 1 Jan 2026.
- 17 Nov 2020 Planned primary completion date changed from 1 Aug 2024 to 1 Jan 2026.